Citations

Clear

237 citation(s) found for "Veronica, N".

An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn, Winston , Li, Yanming , Singal, Ashwani K. , Díaz, Luis Antonio , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Pérez, Diego , Gomez, Jaime, Escarate, Rodrigo , Ramírez, Carolina , Morales‐Arráez, Dalia , Qian, Steve , Ahn, Joseph , Buryska, Seth , Mehta, Heer , Dunn, Nicholas , Bumbu, Andreea , Horhat, Adelina , Attar, Bashar, Agrawal, Rohit , Echavaría, Victor , Cuyàs, Berta , Poca, María , Maiwall, Rakhi , Rao, Padaki Nagaraja , Guerra-Salazar, Patricia, Kubánek, Natália , Prado, Verónica , Clemente, Ana , Haider, Tehseen, Chacko, Kristina R. , Romero, Gustavo , Pollarsky, Florencia , Toro, Luis, Yaquich, Pamela, Garrido, María Laura , Dirchwolf, Melisa , Vargas, Vı́ctor , Jiménez, César , García–Tsao, Guadalupe , Ortiz, Guillermo, Kamath, Patrick S. , Shah, Vijay H. , Díaz, Luis A , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Perez, Diego , Ramirez-Cadiz, Carolina , Mehta, Heer , Dunn, Nicholas , Horhat, Adelina , Agrawal, Rohit , Poca, Maria , Soriano, German , Jalal, Prasun K , Kulkarni, Anand V , Skladaný, Lubomir , Pollarsky, Florencia D , Restrepo, Juan C , Mendizabal, Manuel , Marciano, Sebastián , Dirchwolf, Melisa , Vargas, Victor , Jiménez, César , Arrese, Marco , Bataller, Ramon A , Ahn, Joseph C , Singal, Ashwani K , Cuyas, Berta , Dunn, Winston , Simonetto, Douglas A. , Fuentes–López, Eduardo , Zhang, Wei , Waleed, Muhammad Hasnain , Ştefănescu, Horia , Cabezas, Joaquín , Sarin, Shiv Kumar , Jalal, Prasun K. , Tijera, Fatima Higuera‐de la , Kulkarni, Anand V. , Rincón, Diego , Hudson, David, Ortiz, Guillermo, Abraldeṣ, Juan G. , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology | April 12, 2024 | Volume: 80 | Issue: 5 | Pages: 1196-1211

10.1097/hep.0000000000000883 | PMID 38607809 Get It

Background and Aims: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model. Approach and Results: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort’s average 90-day mortality with each center’s approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779–0.844) and 0.799 (0.769–0.830), significantly surpassing legacy models like Maddrey’s Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores (p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts. Conclusions: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it’s accessible at: https://aihepatology.shinyapps.io/ALCHAIN/.
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer
Patell, Kanchi , Mears, Veronica , Storandt, Michael H. , Mahipal, Amit

Mayo Clinic

Expert Opinion on Drug Metabolism & Toxicology | March 18, 2024 | Volume: 20 | Issue: 4 | Pages: 197-205

10.1080/17425255.2024.2332364 | PMID 38497279 Get It

Risk of Autoimmune Disease in Research-Identified Cases of Autism Spectrum Disorder: A Longitudinal, Population-Based Birth Cohort Study
Villarreal, Verónica, Katušić, Maja , Myers, Scott M. , Weaver, Amy L. , Voigt, Robert G. , Katusic, Maja Z, Katusic, Maja Z., Nocton, James J.

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | February 16, 2024 | Volume: 45 | Issue: 1 | Pages: e46-e53

10.1097/dbp.0000000000001232 | PMID 38364086 Get It

ABSTRACT: Objective: Determine the risk of autoimmune disease in research-identified cases of autism spectrum disorder (ASD) compared with referents using a longitudinal, population-based birth cohort. Methods: ASD incident cases were identified from a population-based birth cohort of 31,220 individuals. Inclusive ASD definition based on DSM-IV-TR autistic disorder, Asperger syndrome, and pervasive developmental disorder, not otherwise specified, was used to determine ASD cases. For each ASD case, 2 age- and sex-matched referents without ASD were identified. Diagnosis codes assigned between birth and December 2017 were electronically obtained. Individuals were classified as having an autoimmune disorder if they had at least 2 diagnosis codes more than 30 days apart. Cox proportional hazards models were fit to estimate the hazard ratio (HR) between ASD status and autoimmune disorder. Results: Of 1014 ASD cases, 747 (73.7%) were male. Fifty ASD cases and 59 of the 1:2 matched referents were diagnosed with first autoimmune disorder at the median age of 14 and 17.1 years, respectively. ASD cases had increased risk of autoimmune disease compared with matched referents (HR 1.74; 95% confidence interval [CI], 1.21–2.52). The increased risk was statistically significant among male patients (HR 2.01; 95% CI, 1.26–3.21) but not among the smaller number of female subjects (HR 1.38; 95% CI, 0.76–2.50). Conclusion: This study provides evidence from a longitudinal, population-based birth cohort for co-occurrence of ASD and autoimmune disorders. Thus, children with ASD should be monitored for symptoms of autoimmune disease and appropriate workup initiated.
Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Seddighi, Sahba , Qi, Yue , Brown, Anna‐Leigh , Wilkins, Oscar G. , Bereda, Colleen , Belair, Cédric , Zhang, Yong‐Jie , Prudencio, Mercedes , Keuss, Matthew J. , Khandeshi, Aditya J , Pickles, Sarah , Hill, Sarah E. , Hawrot, James , Ramos, Daniel M. , Roberts, Jessica P. , Sacramento, Erika Kelmer , Shah, Syed Islamuddin , Nalls, Mike A., Colon, J , Reyes, Joel F. , Ryan, Veronica H. , Nelson, Matthew P. , Cook, Casey , Screven, Laurel A. , Kwan, Justin , Mehta, Puja R. , Zanovello, Matteo , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P. , Ahmed, Aisha , Ule, Jernej , Jacobson, Steven , Reich, Daniel S. , Rohrer, Jonathan D. , Malaspina, Andrea , Glass, Jonathan D. , Seyfried, Nicholas T., Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E. , Fratta, Pietro , Qi, Yue A , Khandeshi, Aditya , Yuan, Hebao , Roberts, Jessica , Sacramento, Erika Kelmer , Shah, Syed I , Colón-Mercado, Jennifer M , Reyes, Joel F , Ryan, Veronica H , Cook, Casey N , Li, Ziyi , Screven, Laurel , Mehta, Puja R , Zanovello, Matteo , Hallegger, Martina , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P , Duong, Duc M , Ahmed, Aisha , Secrier, Maria , Ule, Jernej , Jacobson, Steven , Reich, Daniel S , Rohrer, Jonathan D , Dickson, Dennis W , Glass, Jonathan D , Seyfried, Nicholas T , Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Bereda, Colleen , Fratta, Pietro , Li, Ziyi , Dickson, Dennis W. , Ori‬‬, Alessandro , Seyfried, Nicholas T.

Mayo Clinic

Science Translational Medicine | January 26, 2024 | Volume: 16 | Issue: 734 | Pages: No page available

10.1126/scitranslmed.adg7162 | PMID 38277467 Get It

Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43–depleted human iPSC–derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43–depleted human iPSC–derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43–depleted human iPSC–derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.
SAkuraBONSAI: A Prospective, Open-label Study of Satralizumab Investigating Novel Imaging, Biomarker, and Clinical Outcomes in Patients with Aquaporin-4-IgG-seropositive (P15.AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P15-1.002)
Marignier, Romain , Sergott, Robert C. , Anania, Veronica G. , Buffels, Régine, Künzel, Thomas, Lennon‐Chrimes, Siân , Traboulsee, Anthony , Fujihara, Kazuo , Kim, Ho Jin, O’Connor, Kevin C. , Wiendl, Heinz , Wuerfel, Jens , Zamvil, Scott S. , Pittock, Sean J. , Künzel, Thomas, Bennett, Jeffrey L.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.402 Get It

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society
Medina, Aldo Adrian Acosta, Bossert, Dana, Abeykoon, Jithma P. , Amerikanou, Rodothea , Bach, Corrie R. , Hook, C. Christopher , Lang, Min , Petrova‐Drus, Kseniya , Rotemberg, Veronica , Ruan, Gordon , Yabe, Mariko , Zanwar, Saurabh , Goyal, Gaurav , Cao, Xin-Xin , Collin, Matthew , Makras, Polyzois , Abdel‐Wahab, Omar , Bennani, N. Nora , Durham, Benjamin H. , Francis, Jasmine H. , Lang, Min, Lacouture, Mario E. , Rech, Karen L. , Shah, Meera , Young, Jason R. , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4559-4559

10.1182/blood-2023-184911 Get It

Purpose: The discovery of MAPK/ERK pathway mutations has led to the approval of MEK-inhibitor (MEKi) cobimetinib in histiocytic neoplasms. However, the pivotal clinical trial that led to the approval of cobimetinib included only 4 patients with Langerhans cell histiocytosis (LCH). Therefore, there is a need to define outcomes with MEKi therapy in patients with LCH. We undertook a multi-center collaboration through the Adult LCH Working Group for the Histiocyte Society to address this gap in knowledge. Methods: Adults with LCH who received MEKi therapy were included from five institutions. Objective response rate (ORR) was evaluated using PET/CT criteria, and CT/MRI if PET scan was not available; response categories were categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Progression-free (PFS) and overall survival (OS) were calculated from the time of targeted therapy initiation. Risk organ disease was defined as liver, spleen, or bone marrow involvement. Results: 25 adults with LCH were included in this study; median age at MEKi initiation 43y (range, 18-85). Most common systems involved at diagnosis were bone (52%), pituitary (44%), and lung (36%). Risk organ involvement was observed in 7 (28%, 6 liver, 1 liver and spleen) and 2 (8%) patients had intra-axial CNS involvement. Median lines of prior therapy received were 2 (range: 1-5), and 4 (16%) patients received MEKi in first-line. MAPK/ERK pathway status was assessed via target capture next generation sequencing (NGS) in 22 (96%) cases. Amongst those who underwent NGS, alterations identified included: BRAF V600E (2/22, 9%), BRAF deletions (11/22 50%), MAP2K1 or MEK mutations (4/22, 18%), and MAPK1 or ERK2 (n=1, 5%). Overall, 5 patients also received BRAF inhibitors (4 patients as first therapy prior to MEKi and 1 concomitantly due to BRAF V600E positive melanoma). Specific MEKi agents utilized included cobimetinib (n=13) and trametinib (n=12). Among the response evaluable patients (n=23), ORR to MEKi treatment was 78% (9 CR, 9 PR, 4 SD, 1 PD). Among the 7 patients with liver involvement, responses were seen in 2 (29%) cases. ORR did not significantly differ according to mutation status among those with NGS data (78% MAPK mutated vs. 100% unmutated; p=1.0). In this subcohort, all of the 4 cases that did not respond to MEKi had liver involvement; 3 had BRAF deletions (2 SD and 1 PD), and one had MAPK1 mutation (SD). Median follow-up duration after MEKi initiation in the entire cohort was 18 months (95% CI 6 - 30). The median PFS and OS were not reached; 2-year PFS and OS were 78.1% and 79.9%, respectively (Figure 1A). The median PFS was much shorter in those with liver involvement (7 months [95% CI 0 - 14]) compared with those without liver disease (not reached [95% CI 19-not reached] P=0.047; Figure 1B). PFS did not differ significantly between MAPK pathway mutated and unmutated patients (p=0.34) Adverse events (AEs) were reported in 36% (n=9) and most commonly included rash (n=5) and fatigue (n=3). Four patients experienced grade 3-4 AEs including rash, fatigue, and thrombocytopenia. Common causes of MEKi discontinuation included AEs (n=3), progression (n=2), and drug holiday (n=2). At last follow-up, 5 patients died and 18 remained on MEKi. Death was attributable to LCH (n=3), concomitant malignancy (n=1), or unknown causes (n=1). Conclusions: In our multi-institutional study of adults with LCH, we found MEKi therapy to be highly efficacious. However, liver involvement correlated with a lack of response and worse PFS, while mutational status did not. Future studies are needed to evaluate optimum treatment for high-risk subgroups of LCH like liver disease.
Engaging Underrepresented Patients in Hematology Clinical Trials through the LLS Impact (Influential Medicine Providing Access to Clinical Trials) Research Grant: A Multi-Institutional Effort
Copeland, Zachary , Nelson, Erik , Logan, Nina, Jack, Kellie, Leautaud, Veronica , Philip, Lammers, Goorha, Salil, Randolph, Brion, Cohen, Jonathon B. , Kives, Melissa , Greenberger, Lee M. , Flowers, Christopher R. , Smith, Clayton A. , Leonard, John P. , Nowakowski, Grzegorz S. , Biltibo, Eden Ayele , Copeland, Zachary, Nelson, Erik, Johnston, Jamie, Yaffe, Michael B. , Siddiqi, Tanya , Phillips, Erica Lyn , Savona, Michael R.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 7237-7237

10.1182/blood-2023-191067 Get It

Introduction: Despite governmental and industry-sponsored efforts, clinical trial participation among rural residents and racial and ethnic minorities remains low. The NIH Revitalization Act of 1993 directed the NIH to establish guidelines for inclusion of women and minorities in clinical research. In 2015, the Food and Drug Administration launched an action plan to improve the quality of demographic subgroup data collection, identify barriers to enrollment, employ strategies to increase participation, and promote transparency of related data. However subsequent studies (Green et al. Health Aff. March 2022, Kanapuru et al. Blood Advances. March 2022.) showed no improvement in participation of racial minorities, including Blacks and Hispanics since this plan was enacted. Various complex system- and individual-based factors, including lack of clinical trial availability; lack of diversity in the investigator work force; scant patient and provider awareness of clinical trials; lack of trust in the health care system; and issues with access to care-often driven by financial, geographic, or social constraints (Allison et al. Cureus. Apr 2022.), and stringent eligibility criteria are deemed responsible. The Leukemia & Lymphoma Society (LLS) IMPACT (Influential Medicine Providing Access to Clinical Trials) research grant strives to bridge this unrelenting care gap. Methods: The LLS IMPACT program includes a 5-year research grant which was launched in 2021. The IMPACT grants support the establishment of clinical trial networks involving academic cancer centers (“Hubs”) linked to community clinics and oncology centers (“Spokes”). The program's overall goal is to provide patients access to trials through participation at the community sites. Initially, 3 institutional sites were selected to participate. These institutions had unique and tailored strategies to improve engagement of underrepresented patients, including black, indigenous, people of color, Hispanic, Latina/Latino, and people from rural communities in vastly different climates and local cultures. The IMPACT grant expanded to encompass 4 additional sites given the imminent needs and clamor of the hematology clinical trials community (Figure 1A). The catchment areas and strategies employed at each institution are summarized in the table (Figure 1B). Results: At the start of the grant period, focus was on building clinical research infrastructure and opening non-interventional clinical trials to teach personnel about clinical research and create relationships with patients. Other programs such as webinar series, tumor boards, technological advancements, and educational workshops were also established to enhance engagement among physicians, match patients to clinical trials, and to provide clinical trial education to potential patients. One trial that has seen early success is the CHIVE IMPACT trial, a non-interventional registry and biorepository which has enrolled 24 patients at a rural and underserved site as of July 2023. The purpose of CHIVE is to enroll patients who have clonal hematopoiesis (CH) or are at risk of CH and follow prospectively in efforts to understand risk of progression and potential for early intervention. The Universal Protocol is another biorepository trial which has more than tripled its enrollment number at a community site between 2021 and 2022. Of the 63 patients enrolled in 2022, 66% of them identified as a race other than White. As our core goal is to increase access to interventional trials, we hope to bring industry sponsored phase II and phase III studies to underrepresented areas that serve a broad patient population. Lack of financial resources, lack of transportation and distance to trial sites, and residual distrust of the medical community (e.g., legacy of Tuskegee experiments) are barriers the grantees are focused on overcoming to enroll the intended populations into clinical trials. Conclusion: The innovative strategies employed to expand access to clinical trials for underrepresented population at the various institutions through the LLS's IMPACT research grant can be utilized during clinical trials design and implementation phases to improve generalizability of clinical trials in hematologic malignancies. In the third year of this program, 7 participating sites are engaging impactful strategies (Figure 1B) which will be reported at the end of the grant period.
Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease
Reiner, Anne S. , Bossert, Dana, Sigler, Allison , Buthorn, Justin J. , Rotemberg, Veronica , Rampal, Raajit K. , Reiner, Anne S , Goyal, Gaurav , Lacouture, Mario E. , Francis, Jasmine H. , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4557-4557

10.1182/blood-2023-184879 Get It

Introduction The treatment of Erdheim-Chester disease (ECD) has been revolutionized by the discovery of MAPK/ERK pathway mutations, most common being BRAF-V600E (50%). The US-FDA approved single-agent vemurafenib for BRAF-V600-mutated ECD in 2017 based on a phase II trial that included 22 patients with ECD and 4 with Langerhans cell histiocytosis (LCH), resulting in 100% overall response rate (ORR) by FDG-PET criteria (Diamond et al. JAMA Onc 2018). However, adverse events (AEs) to vemurafenib led to treatment interruption and/or dose modification in all patients, and drug discontinuation in 8 (31%) patients. Long-term outcomes and tolerability of BRAF-inhibitor (BRAFi) monotherapy in real world setting are unknown. In this study, we aimed to address these questions utilizing a large cohort of patients with ECD. Methods Registry-based ( NCT03329274) study of patients with ECD who received BRAFi (vemurafenib or dabrafenib) as any line of treatment. The registry captures detailed longitudinal clinical, treatment, and outcomes data through medical record abstraction. For this study, we focused on the events of discontinuation, dose reductions, and AEs to BRAFi therapy. Time-to-event analyses were conducted using Kaplan-Meier method from the date of initiation of BRAFi. Primary endpoint of the study was event-free survival (EFS), defined as time to progression of disease, discontinuation or alteration of therapy due to any cause (including addition of a MEK inhibitor), or death. Secondary endpoints included progression-free survival (PFS), defined as time to progression of disease or death, and overall survival (OS). Results We included 64 patients with ECD (including 7 with mixed ECD/LCH) in this study. Median age at diagnosis was 56y (range, 26-77) and at initiation of BRAFi was 57y (range, 26-77). Of these, 59 (92%) were BRAF-V600E, 2 (3.1%) were BRAF-wildtype, 1 had BRAF-V471F, 1 had BRAF-PICALM fusion, and 1 had unknown BRAF status. The distribution of organ involvement was bone (91%), neurologic (78%), brain parenchyma (62%), cardiovascular (58%), retroperitoneum (58%), skin (25%), and pulmonary (19%). BRAFi therapy was used as first-line in 38 (59.3%) and as subsequent line in the rest (median 1, range 1-7). The most common initial BRAFi used was vemurafenib (80%) followed by dabrafenib (20%). The median starting dose of vemurafenib was 720 mg bid (range 480-960) and end dose was 480mg bid (range, 240-480). The median start dose of dabrafenib was 100mg bid (range 50-150) and end dose was 50mg bid (range 50-100). Initial dose reduction of BRAFi was required due to AEs in 28 of 52 cases (54%) with final dose data available, encompassing cutaneous (43%), generalized symptoms or fatigue (18%), &gt;1 system affected (14%), lab abnormalities (11%), musculoskeletal (7%), and other (7%) toxicities. Of 60 patients with response data, a response was seen in 51 patients or 85% (42 partial response, 9 complete response, 8 stable disease, and 1 progressive disease). The median follow-up duration was 3.9 years (range 0.2-8.8). Single-agent BRAFi therapy was discontinued in 38 (59%) patients who received it initially (vemurafenib 63% vs. dabrafenib 46%, p=0.28). Reasons for discontinuation included AEs (n=20, 53%), addition of MEK-inhibitor (18%) for reducing cutaneous toxicities (n=5) or augment CNS response (n=2), disease progression (n=4, 11%), death (n=3, 8%), or others (n=4, 11%). 17 patients were rechallenged with a BRAFi after initial discontinuation, and 6 (35%) discontinued it again. The median EFS for the entire cohort from first BRAFi treatment was 2.99y (95% CI 1.6-4.8) and from second BRAFi was 2.82y (95% CI 1.19- not reached). The median PFS and OS were not reached, and 4 patients died at last follow-up (3 from ECD). Conclusions Almost 5 years after the FDA approval of vemurafenib for ECD, our real-world study from long-term follow-up of a large cohort of patients highlights high response rates, but at the cost of adverse events leading to dose reductions and treatment discontinuation in a large subset. Our results also highlight the entity of disease progression on BRAFi therapy. Our results underscore the importance of developing therapies that are efficacious and well-tolerated in this incurable disease.
Local control and survival after stereotactic radiosurgery for colorectal cancer brain metastases: an international multicenter analysis
Singh, Raj , Legarreta, Aimé Parra , Bowden, Greg , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Eldin, Reem Emad, Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Hess, Judith, Templeton, Kelsey, Zhang, Xiaoran , Wei, Zhishuo , Pikis, Stylianos , Mantziaris, Georgios , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Kersh, Charles R. , Lee, Cheng-chia, Niranjan, Ajay , Hadjipanayis, Constantinos G., Lunsford, L. Dade , Sheehan, Jason P. , Mantziaris, Georgios , Perlow, Haley K , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mallela, Arka N. , Mathieu, David , Palmer, Joshua D. , Elhamdani, Shahed, Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 11, 2023 | Volume: 140 | Issue: 5 | Pages: 1233-1242

10.3171/2023.8.jns231231 | PMID 37948682 Get It

OBJECTIVE The goal of this study was to characterize local tumor control (LC), overall survival (OS), and safety of stereotactic radiosurgery for colorectal brain metastasis (CRBM). METHODS Ten international institutions participating in the International Radiosurgery Research Foundation provided data for this retrospective case series. This study included 187 patients with CRBM (281 tumors), with a median age of 62 years and 56.7% being male. Most patients (53.5%) had solitary tumors, although 10.7% had > 5 tumors. The median tumor volume was 2.7 cm3 (IQR 0.22–8.1 cm3), and the median margin dose was 20 Gy (IQR 18–22 Gy). RESULTS The 3-year LC and OS rates were 72% and 20%, respectively. Symptomatic adverse radiation effects occurred in 1.6% of patients. In the multivariate analysis, age > 65 years and tumor volume > 4.0 cm3 were significant predictors of tumor progression (hazard ratio [HR] 2.6, 95% CI 1.4–4.9; p = 0.003 and HR 3.4, 95% CI 1.7–6.9; p < 0.001, respectively). Better performance status (Karnofsky Performance Scale score > 80) was associated with a reduced risk of tumor progression (HR 0.38, 95% CI 0.19–0.73; p = 0.004). Patient age > 62 years (HR 1.6, 95% CI 1.1–2.3; p = 0.03) and the presence of active extracranial disease (HR 1.7, 95% CI 1.1–2.4; p = 0.009) were significantly associated with worse OS. CONCLUSIONS Stereotactic radiosurgery offers a high LC rate and a low rate of symptomatic adverse radiation effects for the majority of CRBMs. The OS and LC favored younger patients with high functional performance scores and inactive extracranial disease.
Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
Smith, Ashley Wilder , DiMartino, Lisa , Garcia, Sofia F. , Mitchell, Sandra A. , Ruddy, Kathryn J. , Smith, Justin D. , Cahue, September, Cella, David , Jensen, Roxanne E. , Hassett, Michael J. , Hodgdon, Christine, Richardson, Kimberly, Kroner, Barbara L, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Farisiv, Nicolas, Flores, Anne Marie, Garcia, Martha, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, McCleary, Nadine J. , Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearsonil, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tesch, Nathan , Tramontano, Angela C. , Jensen, Roxanne E , Osarogiagbon, Raymond U , Cheville, Andrea L , Mitchell, Sandra A , Garcia, Sofia F , Wong, Sandra L. , Kroner, Barbara, Osarogiagbon, Raymond U. , Popovic, Jennifer R. , Schrag, Deborah , Cheville, Andrea , Kroner, Barbara L, Griffin, Joan M. , Ardini, Mary-Anne , Austin, Jessica D. , Barrett, Fiona, Bass, Michael , Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Preiss, Liliana , Reich, James, Richardson, Joshua E. , Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JNCI Cancer Spectrum | November 6, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/jncics/pkad073 | PMID 37930033 Get It

AbstractCancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium’s conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.